Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Bio Diagnostics & Testing

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BUX within the last 6 months
See all filings within the past 6 months

Company News

Jul 14, 2022 08:30 ET
BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-year ended March 31, 2022
Read full article
Jun 21, 2022 08:30 ET
BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that it has been successful in obtaining a novel patent in Japan, No. 7038044, further strengthening the Company's intellectual property position worldwide and coverage of its blood-based technology for early lung cancer detection and screening. The Japan Patent Office is the first to issue patent on the Company's biomarker panel for detecting lung cancer, which belongs to a large family of patents that BioMark owns, and complements similar patents currently pending in Canada, China, Europe, and US.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 202284-100
Jun 30, 2022184-1,845
Jun 15, 20222,0292,000
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BioMark Diagnostics Inc. is a Canada-based oncology-focused company, which is developing its cancer diagnostic business. The Company's cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The Company is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The Company has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.

See business summary



Search (past week) for $BUX.CA

  • No tweets found